Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash & Equivalents (2019 - 2025)

Immunocore Holdings' Cash & Equivalents history spans 4 years, with the latest figure at $467.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 2.63% year-over-year to $467.7 million; the TTM value through Dec 2025 reached $467.7 million, up 2.63%, while the annual FY2025 figure was $467.7 million, 2.63% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $467.7 million at Immunocore Holdings, down from $498.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $832.8 million in Q1 2024 and bottomed at $402.5 million in Q4 2022.
  • The 4-year median for Cash & Equivalents is $482.4 million (2025), against an average of $510.7 million.
  • The largest annual shift saw Cash & Equivalents increased 9.98% in 2023 before it crashed 42.74% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $402.5 million in 2022, then rose by 9.98% to $442.6 million in 2023, then rose by 2.96% to $455.7 million in 2024, then grew by 2.63% to $467.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Cash & Equivalents are $467.7 million (Q4 2025), $498.4 million (Q3 2025), and $487.9 million (Q2 2025).